Brain Circuitry Associated with the Development of Substance Use in Bipolar Disorder and Preliminary Evidence for Sexual Dimorphism in Adolescents

Elizabeth T.C. Lippard¹,², Carolyn M. Mazure¹,³, Jennifer A.Y. Johnston¹, Linda Spencer¹, Judah Weathers¹,³, Brian Pittman¹, Fei Wang¹, and Hilary P. Blumberg¹,²,³,⁴

¹Department of Psychiatry, Yale School of Medicine, New Haven CT, 06511, USA
²Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven CT, 06511, USA
³Women’s Health Research at Yale, Yale School of Medicine, New Haven CT, 06511, USA
⁴Child Study Center, Yale School of Medicine, New Haven CT, 06511, USA

Abstract

Substance use disorders (SUDs) and mood disorders are highly comorbid and confer a high risk for adverse outcomes. However, data are limited on the neurodevelopmental basis of this comorbidity. Substance use initiation typically occurs during adolescence and sex-specific developmental mechanisms are implicated. In this preliminary study we review the literature and investigate regional gray matter volume (GMV) associated with subsequent substance use problems in adolescents with bipolar disorder (BD) and explore these associations for females and males.

Thirty DSM-IV diagnosed BD adolescents with minimal alcohol/substance exposure completed baseline structural magnetic resonance imaging scans. At follow-up (on average 6 years post-baseline), subjects were administered the CRAFFT interview and categorized into those scoring at high (>2: CRAFFTHIGH) versus low (<2: CRAFFTLOW) risk for alcohol/substance problems.

Lower GMV in prefrontal, insular, and temporopolar cortices were observed at baseline among adolescents with BD reporting subsequent alcohol and cannabis use compared to adolescents with BD who did not (p<0.005, clusters >20 voxels). Lower dorsolateral prefrontal GMV was associated with future substance use in both females and males. In females, lower orbitofrontal and insula GMV was associated with future substance use; while in males, lower rostral prefrontal GMV was associated with future use. Lower orbitofrontal, insular and temporopolar GMV was observed in those who transitioned to smoking tobacco. Findings indicate GMV development is associated with risk for future substance use problems in adolescents with BD, with results implicating GMV development in regions subserving emotional regulation in females and regions subserving executive processes and attention in males.

Corresponding Author: Hilary P. Blumberg, MD, 300 George Street, Suite 901, New Haven, CT 06511, Phone: 203-785-6180; Fax: 203-737-2513; hilary.blumberg@yale.edu.

CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Graphical abstract

This study demonstrates regional gray matter volume decreases that may distinguish adolescents with Bipolar Disorder and elevated risk for future substance use problems. Preliminary findings suggest in females, regions associated with internalizing behavior and affective processing are related to risk; in males, regions associated with attention and other executive processes.

Keywords

Sex Characteristics; Magnetic Resonance Imaging; Substance-Related Disorders; Gray Matter; Depression

INTRODUCTION

Mood disorders and substance use disorders (SUDs) have most often been studied as distinct conditions, yet evidence suggests most individuals with a mood disorder or SUD develop comorbidity (Kessler et al. 1994). Bipolar Disorder (BD) is associated with an especially high rate of comorbid SUDs (DelBello et al. 1999; Goldberg 2001; Heffner et al. 2011; Krishnan 2005). An estimated 60% of individuals with BD present with lifetime prevalence of substance abuse (Cassidy et al. 2001). In adolescents/young adults with BD, especially high rates of alcohol, cannabis, and tobacco use are reported (Leweke and Koethe 2008) with at least 40, 39, and 12% of adolescents/young adults with BD reporting at least weekly use of nicotine, alcohol, or cannabis respectively (Hermens et al. 2013).

Comorbid SUD in BD is associated with more severe illness outcomes, including increased impulsivity (Heffner et al. 2012; Swann et al. 2004; Swann et al. 2008), more severe mood episodes (Nolen et al. 2004; Strakowski and DelBello 2000; Strakowski et al. 2007), cognitive deficits (Levy et al. 2008; Marshall et al. 2012), and an increase in the already high risk of suicide attempts (Dalton et al. 2003; Swann et al. 2005). Despite the importance of understanding this comorbidity, there has been a paucity of study on the neural mechanisms underlying its development.

Neuroimaging studies suggest abnormalities in prefrontal cortex (PFC) neural systems are central in BD. These systems subserve emotion and impulse regulation and include ventral,
rostral and dorsal PFC regions, as well as PFC projection sites, including insular and temporopolar cortices and amygdala (Blond et al. 2012; Strakowski et al. 2012). Evidence also suggests abnormalities in PFC system developmental trajectories in adolescents/young adults with BD (Blond et al. 2012; Blumberg et al. 2004; Gogtay et al. 2007; Kalmar et al. 2009; Najt et al. 2015). The neural systems believed to be involved in BD have substantial overlap with neural systems implicated in SUDs (Adinoff 2004; Goldstein and Volkow 2011; Goodkind et al. 2015; Koob and Volkow 2010; Sullivan and Pfefferbaum 2005), suggesting vulnerability for comorbidity may be related to anatomically overlapping brain regions.

Bipolar Disorder and Comorbid Substance Use Disorders

Few neuroimaging studies have examined SUD comorbidity in BD. Adults with BD and comorbid alcohol abuse/dependence compared to adults with BD without SUDs were found to have lower gray matter volume (GMV) (Nery et al. 2011), functional abnormalities (Hassel et al. 2009), and glutamatergic system deficits in dorsal PFC (Nery et al. 2010). However, tobacco use by these subjects was not reported and could have affected findings (Epstein 1990) as an association of reduced PFC and insula cortical thickness and tobacco use in adults with BD has been reported (Jorgensen et al. 2015). In young adults (18–30 years) with BD, oxidative stress in frontotemporal cortices is exacerbated by risky alcohol consumption and tobacco use (Chitty et al. 2013; Chitty et al. 2014), but it is unclear how pre-existing differences in frontotemporal cortices may contribute to this effect. To our knowledge, no studies have examined alcohol abuse/dependence or tobacco use during adolescence in BD with a focus on neuroanatomical factors involved in comorbidity development.

A pilot study of adolescents with BD, following subjects over two years, showed lower GMV in temporal cortex in those diagnosed with comorbid cannabis abuse/dependence before or after scan (n=7), compared to adolescents with BD without comorbid diagnoses (n=7) (Jarvis et al. 2008). In another study, adolescents/young adults (12–21 years) with BD and comorbid cannabis use disorders (n=25; 7 of whom also had comorbid alcohol abuse/dependence) were observed to have decreases in functional responses of the amygdala, shown to be excessive in adolescents with BD without comorbidity (Bitter et al. 2014). However, tobacco use was not examined in either of these studies and GMV was not assessed in the latter study. While the identification of altered GMV and functional responses in regions subserving emotional regulation in adolescents with BD and substance comorbidity may indicate regions involved in comorbidity development, the subjects were not studied exclusively prior to the development of comorbidity so a direct effect of drug exposure cannot be ruled out.

Sex Differences in Brain: Bipolar and Substance Use Disorders

It is well established that there are fundamental sex differences in brain, for example extending from in utero fetal hormone programming (Goldstein et al. 2014) through subsequent brain structure, function and chemistry (Cosgrove et al. 2007). Most brain-based diseases have sex differences in either prevalence, susceptibility, age of onset, presentation, course, prognosis, medication response, treatment outcome, and/or mortality (Institute of Neurosci Res. Author manuscript; available in PMC 2017 July 02.
Sex differences also are reported in addiction processes (Becker and Hu 2008; Becker and Koob 2016; Fattore et al. 2008). For example, in females, greater internalizing symptoms, e.g. depression and anxiety, have been associated with tobacco, alcohol, and cannabis use (Bekman et al. 2013; Husky et al. 2008; McChargue et al. 2004; Moitra et al. 2016; Saraceno et al. 2012; Weinberger et al. 2009; Weinberger et al. 2013a); while in males, associations with externalizing behaviors, e.g. aggressive actions, and substance use have been found (Heron et al. 2013; Steinhausen et al. 2007; Tarter et al. 2009). Sex differences have also been demonstrated in prevalence, risk, and clinical correlates of alcoholism in adults with BD (Frye et al. 2003), including greater number of depressive episodes in females. It is unclear what neuroanatomical factors are associated with this sexual dimorphism.

Findings in groups at increased risk for BD and SUDs [e.g. with early life adversity and family history of SUDs (DeVito et al. 2013; Edmiston et al. 2011)] support sex distinctions in brain regions implicated in BD and in SUDs, e.g. greater abnormalities within ventral regions subserving emotional regulation in females versus dorsal regions subserving impulse control in males. Sex differences in neurochemical abnormalities in the dorsal PFC in adults with BD and comorbid alcohol abuse/dependence have also been found. Specifically, one study suggested that glutamatergic abnormalities in the dorsal PFC are associated with comorbidity in males, but not females; while myo-inositol abnormalities in dorsal PFC are associated with comorbidity in females, but not males (Nery et al. 2010). Although research suggests sex-specific mechanisms in the development of SUDs (Ceylan-Isik et al. 2010; Holmila and Raitasalo 2005; Kuhn 2015; Verplaetse et al. 2015), how sexual dimorphism may contribute to development of SUDs in BD is unknown.

The Purpose of the Current Study

The goal of this preliminary study was to identify regional GMV associated with future development of substance use problems. We assessed relationships between GMV measures on high resolution structural magnetic resonance imaging (sMRI) scans of adolescents with BD who had minimal to no prior alcohol or other substance exposure at baseline, but reported substance use at follow-up on average 6 years later. Specific substances that were reported at follow-up were tobacco, alcohol and cannabis. We also conducted a secondary analysis exploring patterns of regional GMV involvement in females and males. We hypothesized an inverse association between baseline GMV in PFC, insular and temporopolar cortices, and amygdala and severity of future substance use problems, with females showing more associations with future substance use in ventral system components subserving emotional regulation (Blond et al. 2012) and males in rostral and dorsal system components subserving impulse regulation (Bari and Robbins 2013).

MATERIALS AND METHODS

Participants

Subjects who were assessed and scanned in a cross-sectional study and consented to being re-contacted were re-contacted and recruited if they met inclusion and did not meet exclusion criteria. Participants included 30 adolescents/young adults diagnosed with BD...
[mean age at baseline + standard deviation (SD)= 16+2 years; 29 (97%) BDI, 1 (3%) BDII; 50% female; mean age at follow-up= 22+3 years] (see Table 1 for participant characterization). The presence/absence of psychiatric diagnoses and mood state at time of neuroimaging were confirmed with the Structured Clinical Interview for DSM-IV Diagnosis (First 1995) for participants ≥18 years and the Kiddie-Schedule for Affective Disorders and Schizophrenia (Kaufman et al. 1997) for participants <18 years. At baseline assessment, all participants completed sMRI. At follow-up assessment, on average 6+2 years after baseline assessment, subjects completed the CRAFFT interview to assess alcohol and substance use problems since baseline assessment.

As the aim of this study was to examine baseline GMV as a predictor of future alcohol and substance use problems, subjects were excluded if at baseline they self-reported more than minimal alcohol and/or cannabis exposure or ever having used cocaine, opioids, phencyclidine, hallucinogens, or solvents/inhalants. Sixty-three percent of subjects (11 males, 8 females) reported never trying alcohol or any other illicit substances or having tried a sip of alcohol once at a family gathering. Remaining subjects reported having tried alcohol or cannabis once or on a few occasions with peers. Subjects were not excluded for tobacco use. At baseline and follow-up assessment, tobacco use was assessed as smoking using the Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al. 1991). At baseline, two subjects (7%) reported current smoking and one subject (3%) reported past history of, but not current, smoking. Transition to smoking was studied in remaining subjects. In addition to the 3 subjects with a history of smoking tobacco at baseline, 11 individuals (41%; 7 females) with no tobacco use at baseline reported history of smoking at follow-up (8 were currently smoking at follow-up assessment; 4 female current smokers at follow-up). Sixteen individuals (53%; 6 females) reported no history of smoking tobacco at either time point.

On the neuroimaging day, urine toxicology screens for substances of abuse (cannabis, cocaine, amphetamine, methamphetamine, methadone, opiates, phencyclidine, barbiturates, and benzodiazepines) were negative for all subjects. Exclusion criteria included history of neurological illness, including head trauma with loss of consciousness for ≥5min, or major medical illness. Subjects were not excluded for comorbidities or family history of psychiatric disorders as there are high rates of these in individuals with BD and excluding decreases generalizability. After complete description of the study, written informed consent was obtained from subjects ≥18 years, and assent and parent/guardian permission from subjects <18, in accordance with the Yale School of Medicine human investigation committee.

**MRI Acquisition and Processing**

High-resolution sMRI data were acquired for each subject with a 3-Tesla Siemens Trio MR scanner (Siemens, Erlangen, Germany). The sMRI sagittal images were acquired with a three-dimensional magnetization prepared rapid acquisition gradient echo (MPRAGE) T1-weighted sequence with parameters: repetition time (TR)=1500ms, echo time (TE)=2.83ms, matrix 256 × 256, field of view (FOV)=256mm x 256mm2, and 160 one-mm slices without gap and two averages. Images were processed with the DARTEL toolbox within Statistical and Parametric Mapping 12 (SPM12) (http://www.fil.ion.ucl.ac.uk/spm). The SPM
segmentation function and SPM tissue probability maps for gray matter, white matter and cerebral spinal fluid were implemented for bias correction and segmentation and used to create DARTEL templates using the “Run Dartel (create Templates)” command under DARTEL tools (Henley et al. 2014; Malone et al. 2015). Data were normalized to Montreal Neurological Institute (MNI) space and smoothed with an 8mm full-width-at-half-maximum (FWHM) isotropic kernel.

**Alcohol and Substance Use**

Subjects were administered the CRAFFT interview (Knight et al. 1999), which consists of 6 yes/no questions inquiring about risk indicators or problems experienced from alcohol or drug use. CRAFFT is an acronym with each letter representing one of 6 items. C relates to history of driving or riding in a Car driven by someone who had been using alcohol/drugs, R if used alcohol/drugs to Relax, A if used alcohol/drugs while Alone, F if Forgotten things one did while using alcohol/drugs, F whether told by Family/Friends to cut down on alcohol/drug use, and T whether gotten into Trouble while using alcohol/drugs. The questions are equally weighted (one point for each yes answer). The CRAFFT has substantial empirical support as a substance use screening instrument for adolescents in multiple settings, including outpatient general medical and inpatient psychiatric settings (Cummins et al. 2003; Dhalla et al. 2011; Knight et al. 2003; Knight et al. 2002; Knight et al. 1999; Oesterle et al. 2015; Pilowsky and Wu 2013). A score of ≥2 has been used as the threshold optimal for identifying alcohol/substance problems (Knight et al. 2002; Knight et al. 1999). At follow-up, 19 (63%) participants had a CRAFFT score of ≥2 (CRAFFT \( \text{mean} \pm \text{SD} = 2.3 \pm 2.1 \); scores ranged from 0–6 and showed a normal distribution in both males and females).

**Additional Assessments**

Participants were assessed with the Young Mania Rating Scale (Gracious et al. 2002; Young et al. 1978) and the 2-subtest version (Matrix Reasoning and Vocabulary) of the Weschler Abbreviated Scales of Intelligence (Psychological-Corporation 1999). Additionally, at baseline assessment, 27 participants [14 female (51%)] completed the Child Depression Rating Scale (CDRS) (Emslie et al. 1990) and 25 participants [12 female (48%)] the Barratt Impulsiveness Scale (BIS)-11 or BIS-11a. The BIS is a self-reported measure of trait impulsivity. The total BIS score is the sum of three subscale scores: non-planning impulsivity, cognitive-attentional impulsivity, and motor impulsivity. BIS-11a scores were prorated to BIS-11 scores as previously described (Gilbert et al. 2011; Patton et al. 1995).

**Statistical Analyses**

**Demographic and Clinical Feature Analysis**—Subjects were categorized into those scoring at high (≥2: CRAFFT\(_{\text{HIGH}}\)) versus low (<2: CRAFFT\(_{\text{LOW}}\)) risk for alcohol and substance use problems. Independent t-tests were performed to assess group differences in age at baseline scans, age at follow-up, interval between baseline scan and follow-up, and baseline IQ, years of education, Young Mania Rating Scale, CDRS and BIS (total and subscale) scores. Chi-square (or Fisher’s exact) tests were used to examine whether clinical factors differed by CRAFFT group at baseline (see Table 2 and Table 3). These included mood state (euthymic, depressed, elevated), history (yes/no) of hospitalization, rapid
cycling, psychosis, suicide attempt, smoking tobacco, comorbid diagnosis (yes/no) of simple/specific phobia, ADHD, ODD, CD, or separation anxiety, and medication subclasses (on/off). Analyses were repeated stratified by sex. Additionally, a Chi-square test was used to assess if the number of individuals transitioning to smoking tobacco between baseline and follow-up assessment differed by CRAFFT group (excluding 3 individuals with baseline history of tobacco use). A Fisher’s exact test was used to assess whether CRAFFT<sub>HIGH</sub> males and females differed in the number of individuals who transitioned to smoking tobacco between baseline and follow-up assessment. Results were considered significant at p<0.05.

**SPM Voxel-Based Analysis**—A two-sample t-test was conducted in SPM12 to assess CRAFFT<sub>HIGH</sub> versus CRAFFT<sub>LOW</sub> group differences in baseline GMV, including data from all subjects. For hypothesized regions, PFC, insular and temporopolar cortices and amygdala, results were considered significant at p<0.005 (uncorrected) and clusters >20 voxels. This threshold was chosen to balance for type I and type II errors in preliminary studies (Forman et al. 1995; Lieberman and Cunningham 2009). For remaining brain regions, findings were considered as significant with p<0.05 Family-Wise Error (FWE)-corrected and a threshold of 10 voxels for multiple comparisons. Mean GMV, extracted from clusters showing significant differences between CRAFFT groups, were calculated. Post hoc analysis was performed to assess effect of CRAFFT group when covarying age or IQ at baseline, with GMV from extracted clusters as the dependent variables. To further confirm regional GMV association with CRAFFT outcome, the relationship between mean GMV in significant clusters with total CRAFFT score was assessed with Pearson correlations across all subjects. Correlations were repeated stratified by sex to explore sex-related patterns in volumetric features associated with the development of substance use problems. Correlation analyses were also performed across all subjects, and stratified by sex, to assess relationship between GMV and baseline CDRS or BIS (total and subscale) scores. Based on our <i>a priori</i> hypotheses, GMV from clusters within rostral PFC (rPFC) and dorsolateral PFC (dIPFC) showing a significant difference between CRAFFT groups were assessed for relationship with BIS (total and subscales) scores; GMV from clusters within orbitofrontal cortex (OFC) and insular and temporopolar cortices were assessed for relationship with baseline CDRS scores. Post hoc analyses above were repeated after removing 3 subjects with a history of tobacco use at baseline.

A t-test was used to explore differences in extracted GMV, from significant regions identified in the CRAFFT group analysis above, between individuals who never smoked tobacco at either assessment (N=16) and those who transitioned to smoking tobacco between baseline and follow-up assessment (N=11). Regional GMV identified as being associated with transitioning to smoking tobacco were explored across all subjects who transitioned and were currently smoking tobacco at follow-up using Pearson correlations to determine relationships with total FTND scores.

We performed t-tests to explore associations between mean GMV in significant clusters with clinical and medication subclass factors present and absent at baseline in N>5 subjects, including mood state (euthymic versus elevated), history (yes/no) of hospitalizations, rapid cycling, lifetime psychosis, and if taking (off/on) an antipsychotic, anticonvulsant, stimulant,
Analyses were repeated stratified by sex for clinical factors present or absent at baseline in N>5 female or male subjects, including history (yes/no) at baseline of rapid cycling, lifetime psychosis, and if taking (off/on) an antipsychotic at baseline. In females, we assessed effects of taking an anticonvulsant and differences between subjects transitioning to smoking tobacco between baseline and follow-up assessments (N=7 females), compared to those reporting no history of smoking at either assessment (N=6 females). In males, we assessed effects of comorbid ADHD and taking a stimulant or lithium at baseline assessment, but did not assess for smoking conversion as only 4 males converted. These post hoc analyses were considered significant at p<0.05. All significant results are reported below.

RESULTS

Differences in Baseline Demographic and Clinical Features Between CRAFFT Follow-up Groups

In baseline analyses across all subjects, the CRAFFT\textsubscript{HIGH} group had higher CDRS scores ($t_{25}$=2.11, p=0.045). Within females, the CRAFFT\textsubscript{HIGH} group had a trend towards higher CDRS scores ($t_{13}$=2.14, p=0.054). No significant differences in BIS (total or subscales) scores were observed (see Table 3 for summary of CDRS and BIS scores). More CRAFFT\textsubscript{HIGH} males, compared to CRAFFT\textsubscript{LOW} males, had comorbid diagnoses of ADHD (78% versus 17% respectively, p = 0.04, Fisher’s exact test) and were taking a stimulant at baseline (78% versus 17% respectively, p = 0.04, Fisher’s exact test). Overall, the CRAFFT\textsubscript{HIGH} group had more individuals transition to smoking tobacco at follow-up assessment (56% versus 18% respectively, $\chi^2$=3.9, df=1, p=0.048). There was no difference between CRAFFT\textsubscript{HIGH} females and males in number of individuals who transitioned to smoking tobacco between baseline and follow-up assessment (63% CRAFFT\textsubscript{HIGH} females versus 50% CRAFFT\textsubscript{HIGH} males respectively, $\chi^2$=0.25, df=1, p=0.61). There were no other differences in demographic/clinical factors between CRAFFT groups overall or within females or males (see Table 2).

Differences in Baseline GMV Between CRAFFT Follow-up Groups

Within our \textit{a priori} hypothesized regions, the CRAFFT\textsubscript{HIGH} group had lower GMV in left OFC [Brodmann area (BA) 11, MNI coordinates: x=−18mm, y=27mm, z=−20mm, cluster=45 voxels], right rPFC (BA10, x=18mm, y=60mm, z=3mm, cluster=35 voxels), left dIPFC (BA9, x=−28mm, y=27mm, z=38mm, cluster=79 voxels), and right insular (x=44mm, y=−8mm, z=−2mm, cluster= 175 voxels) and left temporopolar cortices (BA38, x=−48mm, y=20mm, z=−26mm, cluster=164 voxels) (Figure 1). The CRAFFT\textsubscript{HIGH} group did not show any areas of greater GMV in hypothesized regions. No significant differences in GMV were observed outside of hypothesized regions.

Significance remained in hypothesized regions when covarying age or when covarying IQ. Across all subjects, total CRAFFT scores were negatively correlated with extracted mean GMV of clusters within the OFC ($r$=−0.44, n=30, p=0.016), rPFC ($r$=−0.51, n=30, p=0.004), dIPFC ($r$=−0.63, n=30, p=0.0002), and insula ($r$=−0.45, n=30, p=0.013). Insula GMV was negatively correlated with baseline CDRS scores ($r$=−0.46, n=27, p=0.015). Both females
and males showed a negative correlation between total CRAFFT scores and dlPFC GMV (females: r=−0.69, n=15, p=0.004; males: r=−0.67, n=15, p=0.008). Additionally, females, but not males, showed a negative correlation between total CRAFFT scores and OFC (r=−0.74, n=15, p=0.002) and insula (r=−0.69, n=15, p=0.004) GMV. Males, but not females, showed a negative correlation between total CRAFFT scores and rPFC GMV (r=−0.62, n=15, p=0.01). Within females, a trend for a negative correlation between insula GMV and baseline CDRS scores (r=−0.50, n=14, p=0.07) was observed. When excluding the 3 subjects with baseline history of tobacco these results were still observed (not shown).

Lower GMV within the OFC (t25=2.98, p=0.006) and insular (t25=2.46, p=0.021) and temporopolar (t25=2.54, p=0.018) cortices was observed in individuals who transitioned to smoking tobacco between baseline and follow-up assessment, compared to individuals who reported no history of smoking tobacco at either assessment. Temporopolar GMV was negatively associated with follow-up FTND scores (r=−0.76, n=8, p=0.03) in individuals who transitioned to smoking tobacco after their baseline assessment and were currently smoking at follow-up. No other significant effects of clinical factors were observed on GMV when looking across all subjects or when investigating within females and males separately.

DISCUSSION

Lower baseline GMV in the PFC, including dlPFC, OFC, and rPFC, and insular and temporopolar cortices, were observed among adolescents with BD who subsequently reported substance use problems with alcohol and cannabis on the CRAFFT interview compared to adolescents with BD who did not. Exploratory analyses supported both common and different patterns of regional GMV associated with substance use development among females and males. Decreased baseline dlPFC GMV was associated with substance use problems in both females and males. Lower baseline OFC and insula GMV was associated with substance use problems in females; lower baseline rPFC GMV was associated with substance use problems in males. Greater depressive symptoms at baseline were associated with greater substance use problems at follow-up, with depressive symptoms related to lower insula GMV, with these associations driven by the female data. Additionally, lower OFC, insular and temporopolar GMV were observed in individuals who transitioned to smoking tobacco, with temporopolar GMV inversely associated with severity of nicotine dependence at follow-up.

Regions in which GMV abnormalities were associated with development of substance use problems in BD are consistent with previous findings in adolescents in the absence of BD with alcohol and substance abuse/dependence (Bava and Tapert 2010), and drug-related processes, including craving, motivational changes, withdrawal symptoms, and relapse/treatment outcomes (Adinoff 2004; Goldstein and Volkow 2011; Koob and Volkow 2010; Naqvi et al. 2014; Sinha and Li 2007). Abnormalities in behaviors subserved by these regions may contribute to vulnerability/risk for substance use problems (Adinoff et al. 2007; Baker et al. 2004; Claus and Hutchison 2012; Li and Sinha 2008; Peeters et al. 2014). Dorsal system components, i.e. the dlPFC and rPFC, are associated with higher order executive functions and behavioral control (Aron et al. 2004; Burgess et al. 2007; Dumonteil et al. 2008; Gilbert et al. 2006; Koechlin and Hyafil 2007; Levy and Goldman-Rakic 2000;
Petrides and Pandya 2007; Ramnani and Owen 2004). Ventral and paralimbic cortical regions implicated, i.e. OFC, insular and temporopolar cortices, are associated with affective processing and regulation, self-awareness, stimulus-reinforcement associations, behavioral control and risky decision making (Clark et al. 2008; Craig 2002; Crowley et al. 2015; Etkin et al. 2011; Fellows 2007; Kringelbach and Rolls 2004; Manes et al. 2002; Modinos et al. 2009; Muhlert and Lawrence 2015; Rolls 2004; Van Leijenhorst et al. 2010; Xue et al. 2010).

**Circuitry Associated with Sex-Related Risk for Substance Problems**

Exploratory findings in regions subserving affective and internal monitoring processes in females are consistent with literature supporting associations between disturbances in affective processing and internalizing symptoms and substance use problems. This has been found in the absence of BD (Boden and Fergusson 2011; Garfield et al. 2015; Hussong et al. 2011) and suggested to be especially salient in the development of substance use problems in females (Bekman et al. 2013; Moitra et al. 2016; Saraceno et al. 2012). The insula has been associated with addictive behavior, postulated to be through involvement in interoceptive aspects of drug craving and seeking (Gaznick et al. 2014; Naqvi et al. 2014; Naqvi et al. 2007). The right posterior insula is suggested to be involved in self-awareness and emergence of a sense of self (Avery et al. 2014; Craig 2002; Farrer et al. 2003). Decreased awareness/insight are implicated in addicted individuals failing to seek treatment (Goldstein et al. 2009). Differences in insula development and related differences in development of awareness/insight during adolescence may contribute to an inability to recognize and relate negative consequences to early drug use increasing the risk for problematic usage. Depression, a risk factor for substance use especially in females (Saraceno et al. 2012), is associated with differences in awareness/insight (Schwartz-Stav et al. 2006; Wiebking et al. 2014; Wiebking and Northoff 2015). An inverse association between insula GMV and number of depressive episodes in BD has been reported (Takahashi et al. 2010). We report associations between greater depression symptomatology, lower insula GMV, and greater substance use problems at follow-up, largely due to data from females. More research is needed in adolescents on the relationships between the insula, depression, constructs of awareness/insight and the development of substance-use related problems, especially in females.

Literature also supports associations between externalizing symptoms and substance use problems. This has been found in the absence of BD (Griffith-Lendering et al. 2011; Miettunen et al. 2014; Oshri et al. 2011; Rogosch et al. 2010) and suggested to be especially salient in the development of substance use problems in males (Heron et al. 2013; Steinhausen et al. 2007; Tarter et al. 2009). Impulsiveness has been suggested as a trait feature of BD that might increase vulnerability for substance use problems (Gilbert et al. 2011; Nery et al. 2013; Swann et al. 2004). We did not detect associations between BIS impulsivity scores and subsequent substance use problems. It is possible this is due to limited power to detect associations particularly in the small male subsample, or that differences in impulsiveness may not have emerged yet in this young sample and future studies examining behavioral trajectories associated with transitioning to substance use disorders may reveal differences. It is also possible that the BIS does not capture relevant
impulsivity constructs. This is supported by work showing risk-taking and novelty seeking may distinguish adults with BD and comorbid SUDs better than BIS impulsiveness scores (Bauer et al. 2015; Haro et al. 2007; Kathleen Holmes et al. 2009).

More males with BD and prospective substance use problems were diagnosed with comorbid ADHD at baseline. Recent work suggests ADHD may increase risk for substance use problems in the absence of BD (Bidwell et al. 2014; Kolla et al. 2016; Urcelay and Dalley 2012) and when comorbid with BD (Perroud et al. 2014). The neuroanatomical factors underlying this association are unclear. Adults with BD and comorbid ADHD, compared to those without, showed greater rPFC dysfunction (Adler et al. 2005). While an association between comorbid ADHD and GMV findings were not detected in this study possibly owing to sample size, males but not females did show an inverse association between rPFC GMV and CRAFFT scores. More work is needed to identify if behavioral constructs associated with rPFC, e.g. executive functions, decision making and response processes (Burgess et al. 2007; Dumontheil et al. 2008; Koechlin and Hyafil 2007), may be particularly salient in development of substance use problems in males with BD.

Regions of GMV differences reported here are associated with hot and cold cognition (Prencipe et al. 2011; Zelazo and Carlson 2012). Adults with BD perform worse on hot and cold cognitive tasks compared to healthy controls (Roiser et al. 2009). Studies suggest females may initiate substance use later than males (Brady and Randall 1999) and it is suggested that hot cognition develops more slowly than cold cognition (Prencipe et al. 2011; Zelazo and Carlson 2012). In light that we report regions associated with hot cognition are predictive in females, while regions associated with cold cognition predictive in males, differences in speed of hot and cold cognitive development may be associated with sex differences in age of risk for substance use initiation. More work is needed to understand sex differences in the development of these processes during adolescence and if these are disrupted in BD.

Lower baseline OFC, insular and temporopolar GMV in adolescents with BD were also associated with transitioning to smoking tobacco. As above, these regions are involved in affective processes, including depression symptomatology (Arnsten and Rubia 2012; Hulvershorn et al. 2011; Pfeifer and Peake 2012; Wang et al. 2011). Findings in these regions are consistent with literature supporting associations between depression and tobacco use in the absence of BD (Cheetham et al. 2015; Graham et al. 2007; Kassel et al. 2003; Weinberger et al. 2013a; Weinberger et al. 2012; Weinberger et al. 2013b). It has been suggested that this relationship is especially salient for tobacco use in females (Husky et al. 2008; McChargue et al. 2004; Weinberger et al. 2009). We did not observe sex-related associations between GMV in these regions and transitioning to smoking tobacco; however, ability to detect associations was limited by sample size. While we did not detect an association between temporopolar GMV and follow-up CRAFFT scores, temporopolar GMV was inversely related to follow-up Fagerstrom scores for nicotine dependence severity suggesting its involvement in development of smoking. Future work is warranted to investigate neuroanatomical specificity for vulnerability/risk for certain drugs types in BD.
Neuroanatomical Factors Associated with Substance Use Problems in Other Populations

Studies of adolescents recruited from school systems, the majority of whom had no history of psychopathology at baseline, report lower dorsal PFC and OFC GMV and less OFC gyrification associated with subsequent alcohol-related problems and initiation of cannabis use (Cheetham et al. 2014; Cheetham et al. 2012; Churchwell et al. 2012; Kuhn et al. 2015). Functional MRI studies of adolescents having no history of psychopathology but genetic risk for substance use problems have shown associations between regional responses during response inhibition or working memory tasks in dorsal PFC, including dlPFC and rPFC, with subsequent substance use problems (Heitzeg et al. 2014; Norman et al. 2011; Squeglia et al. 2012; Wetherill et al. 2013). We are not aware of a study examining adolescents with minimal to no alcohol or substance use at baseline demonstrating associations between baseline insular and temporopolar GMV with prospective substance use problems. As above, a growing body of work suggests insula involvement in drug craving and seeking behavior (Naqvi et al. 2014). One report did show young adults with moderate alcohol use who then transitioned to heavy alcohol use had greater alcohol cue reactivity in the insula (Dager et al. 2014). However, as that study consisted of individuals with moderate alcohol use at baseline, brain effects of alcohol exposure cannot be ruled out.

We did not observe an association between amygdala GMV and subsequent substance use problems in BD. In previous studies examining adolescents who predominantly had no history of psychopathology, associations between amygdala volumes with prospective alcohol/cannabis use were also not detected (Cheetham et al. 2014; Cheetham et al. 2012). This suggests that previous observations of amygdala abnormalities as observed in adolescents/young adults without BD but with cannabis (Gilman et al. 2014; Padula et al. 2015) or alcohol use (Dager et al. 2013) as well as in adolescents with BD and comorbid cannabis use (Bitter et al. 2014) may be related to substance exposure. Additionally, altered amygdala morphology and function in association with substance use has shown genetic and sex-related associations (Benegal et al. 2007; Cacciaglia et al. 2013; Hill et al. 2001; Hill et al. 2013; McQueen et al. 2011). It is therefore possible that genetic heterogeneity and limited power to detect sex-related associations may have confounded ability to detect findings.

To our knowledge, there have not been other reports demonstrating neuroanatomical predictors of subsequent transitions to smoking tobacco. Adolescents/young adult tobacco smokers without BD, compared to non-smokers, show cortical thinning in the OFC (Li et al. 2015) and a negative association between OFC and insula cortical thickness and magnitude of lifetime exposure to tobacco smoke (Li et al. 2015; Morales et al. 2014). Further study on OFC, insular and temporopolar cortices involvement in elevating risk for smoking tobacco is warranted.

Limitations and Future Directions

The size and heterogeneous clinical features of the subject sample in this preliminary study could have limited power to detect associations with substance use. Future studies with larger sample sizes and greater power to identify sex-related circuitry while also systematically assessing clinical factors are needed. We did not assess medication adherence.
at follow-up which could contribute to risk. A strength of the present study is the minimal to no alcohol, cannabis, tobacco and other substance use at baseline; findings of lower GMV associated with prospective substance use problems are therefore unlikely to be due to brain effects of alcohol or other drug exposure. Although the toxicology screens aided determination of recent use, self-reports by subjects could have minimized substance use at baseline. Drug use at follow-up was not assessed by structured interview and subjects could have under reported baseline drug use. We were not able to explore factors associated specifically with alcohol, cannabis or tobacco use as 89% of individuals meeting CRAFFT threshold at follow-up reported use of more than one of these substances. Type I errors are possible given the preliminary nature of this study; we reported p-values uncorrected for multiple comparisons to minimize type II errors (Silver et al. 2011). Future studies are needed to confirm the current findings, including exploratory findings suggesting sex-related circuitry associated with risk, with sufficient power to detect regional differences in non-hypothesized regions and effects of clinical features on risk.

Large scale imaging studies, incorporating permission into consent forms for future re-contact for phone interviews to assess symptomatology, could provide invaluable insight regarding risk factors and development that builds upon already funded research. Research incorporating longitudinal study—examining effects of genetic variations and behavioral constructs, and functional consequences of structural differences identified here—is warranted, including study to disentangle contributions of regions, and interactions between them contributing to development of substance use problems. Functions investigated should include emotional processing and regulation, in addition to executive functions, as these functions may be differently associated with substance use development in females and males. Similar regions of reduced gray matter have been found to be a characteristic that crosses diagnostic boundaries (Goodkind et al. 2015). More work is needed investigating sexual dimorphism in mechanisms driving drug-seeking behavior and transitions to substance use problems in females and males with BD, including environmental/societal influences, and commonalities and distinctions between BD and other psychiatric disorders. The current study did not include an at risk comparison group so diagnostic-associated neuroanatomical factors associated with risk cannot be determined. Future studies focused on mechanisms underlying variation in GMV, and associated outcomes, in BD are needed. The glutamatergic system is involved in adolescent brain maturation (Bossong and Niesink 2010) and abnormalities within this system are implicated in addiction (Pomiery-Chamiolo et al. 2014) and pediatric BD (Spencer et al. 2014). Other factors that could contribute to altered GMV in BD include, but are not limited to, abnormalities in the serotonergic system (Booij et al. 2015) and/or sex hormones. For example, rodent studies suggest estrogen in females can reduce neuron density in ventromedial prefrontal cortex (Juraska and Markham 2004; Markham et al. 2007). Studies examining resilience to developing substance use in psychiatric disorders and at risk populations could reveal novel therapeutic strategies. It is important to note that reduced volume found to be associated with future substance use could be an epiphenomenon of more severe BD symptomatology. Future work is needed to clarify if regions identified here are addiction-specific outside of worse bipolar symptomatology that may elevate risk for substance use.
In Conclusion

This study provides new preliminary evidence that GMV in brain regions with known roles in addiction are involved in risk for developing substance use problems in adolescents with BD. Work reported here in adolescents with BD, taken together with work examining predictors of future substance use in other non-psychiatric samples, suggests PFC abnormalities may be common to risk for developing substance use problems in females and males. Our preliminary findings suggest there may also be sex-related differences in the paths to developing substance use problems in BD with involvement of regions subserving emotional processes, such as the OFC and insula, in females, and regions subserving executive functioning or response processes, such as the rPFC, in males. Future work confirming underlying sex-specific mechanisms could improve detection of individuals at risk and intervention strategies.

Acknowledgments

Acknowledgement of Support: The authors were supported by research grants from the National Institute of Health (NIH) RC1MH088366 (HPB), R01MH070902 (HPB), R01MH069747 (HPB), T32MH014276(ETCL), T32DA022975 (ETCL), and K01MH086621(FW); American Foundation for Suicide Prevention (HPB, ETCL), International Bipolar Foundation (HPB), Brain and Behavior Research Foundation (HPB, FW), and Women’s Health Research at Yale (HPB).

ROLE OF AUTHORS

All authors had full access to the data and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: HPB, ETCL, CMM. Acquisition of data: HPB, ETCL, JAYJ. Analysis and interpretation of data: HPB, ETCL, CMM, JAYJ, LS, JW, BP, FW. Drafting of manuscript: HPB, ETCL, CMM. Critical revision of the manuscript: HPB, ETCL, CMM, JAYJ, LS, JW, BP, FW. Statistical analysis: HPB, ETCL, CMM, BP. Obtained funding: HPB, ETCL. Administrative, technical, and material support: JAYJ, LS. Study supervision: HPB, ETCL.

We thank Susan Quatrano and Philip Markovich for their assistance with the research, Cheryl Lacadie, Karen Martin, Terry Hickey, and Hedy Sarofin for their technical expertise, and the research subjects for their participation.

REFERENCES


Cheetham A, Allen NB, Schwartz O, Simmons JG, Whittle S, Byrne ML, Sheeber L, Lubman DI. Affective behavior and temperament predict the onset of smoking in adolescence. Psychology of


Kolla NJ, van der Maas M, Toplak ME, Erickson PG, Mann RE, Seeley J, Vingilis E. Adult attention deficit hyperactivity disorder symptom profiles and concurrent problems with alcohol and...


Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-balancing the scale. Social cognitive and affective neuroscience. 2009; 4(4):423–428. [PubMed: 20035017]


Bipolar Disorder (BD) and substance use disorders (SUDs) are highly comorbid. This comorbidity often develops in adolescence and is associated with adverse outcomes. We prospectively investigated the relationship of gray matter volume (GMV) to subsequent substance use problems in adolescents with BD. Results indicate substance use problems in BD are associated with lower dorsolateral prefrontal GMV in females and males, lower orbitofrontal and insula GMV in females, and lower rostral prefrontal GMV in males. These common and sex-related findings point to regulatory brain systems that may underlie comorbid substance abuse and serve as targets for early detection and intervention strategies.
Figure 1. Gray Matter Volume Decreases in Bipolar Disorder with Prospective Substance use Problems

The images show the regions of gray matter volume decreases in the bipolar disorder (BD) group with prospective substance use problems (CRAFFT\text{HIGH}), compared to the group with bipolar disorder without prospective substance use problems (CRAFFT\text{LOW}). No regions of gray matter volume increases were observed in the BD CRAFFT\text{HIGH} group compared to BD CRAFFT\text{LOW} group. Significance threshold is p<0.005, cluster >20 voxels. ‘L’ on left of figure denotes left side of brain. The color bar represents the range of T values. BD CRAFFT\text{HIGH} N=19, BD CRAFFT\text{LOW} N=11.
### Table 1
Demographic and Clinical Characterization of Participants

<table>
<thead>
<tr>
<th>Demographics/ Clinical Factors</th>
<th>Participant Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>30</td>
</tr>
<tr>
<td>Age (SD) in years</td>
<td>16 (2)</td>
</tr>
<tr>
<td>Number Female (%)</td>
<td>15 (50%)</td>
</tr>
<tr>
<td>IQ (SD)</td>
<td>101.5 (16.6)</td>
</tr>
<tr>
<td>Years of Education (SD)</td>
<td>10.1 (1.9)</td>
</tr>
<tr>
<td>Young Mania Rating Scale (SD)</td>
<td>2.7 (3.4)</td>
</tr>
<tr>
<td>Mood State [Euthymic(%) / Depressed(%) / Elevated(%)]</td>
<td>22 (73%) / 2 (7%) / 6 (20%)</td>
</tr>
<tr>
<td>Prior Hospitalizations (%)</td>
<td>20 (67%)</td>
</tr>
<tr>
<td>Rapid Cycling (%)</td>
<td>11 (37%)</td>
</tr>
<tr>
<td>Lifetime Psychosis (%)</td>
<td>16 (53%)</td>
</tr>
<tr>
<td>Suicide Attempt (%)</td>
<td>4 (13%)</td>
</tr>
<tr>
<td>Cigarette/Tobacco Use History at Baseline (%)</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Simple/ Specific Phobia (%)</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Attention Deficit Hyperactivity Disorder</td>
<td>10 (33%)</td>
</tr>
<tr>
<td>Oppositional Defiant Disorder</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Conduct Disorder</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Separation Anxiety</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Medicated at scan (%)</td>
<td>27 (90%)</td>
</tr>
<tr>
<td>Antipsychotic (%)</td>
<td>18 (58%)</td>
</tr>
<tr>
<td>Anticonvulsant (%)</td>
<td>11 (37%)</td>
</tr>
<tr>
<td>Stimulant (%)</td>
<td>10 (32%)</td>
</tr>
<tr>
<td>Lithium (%)</td>
<td>9 (30%)</td>
</tr>
<tr>
<td>Antidepressant (%)</td>
<td>5 (16%)</td>
</tr>
<tr>
<td>Benzodiazepine (%)</td>
<td>5 (16%)</td>
</tr>
<tr>
<td>Ketamine (%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Adrenergic Agonist (%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Amantadine (%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Levothyroxine (%)</td>
<td>4 (13%)</td>
</tr>
</tbody>
</table>

1 Elevated mood includes subjects in hypomanic, manic, and mixed mood states.

2 Rapid-cycling reported is lifetime history of rapid cycling.

3 Presence of disorders of childhood were assessed by structured interview in subjects <18 years; percentage is based on the overall sample.

4 Individuals on levothyroxine had hypothyroidism.
Table 2
Differences in Baseline Demographic and Clinical Characterization Between CRAFFT Follow-up Groups

<table>
<thead>
<tr>
<th>Demographics/ Clinical Factors</th>
<th>All Subjects</th>
<th>Male Subjects</th>
<th>Female Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CRAFTLOW (N=11)</td>
<td>CRAFTHIGH (N=19)</td>
<td>p value</td>
</tr>
<tr>
<td>Age at Baseline Scan (SD)</td>
<td>17.1 (2.4)</td>
<td>16.1 (1.6)</td>
<td>0.199</td>
</tr>
<tr>
<td>Age at Follow-up (SD)</td>
<td>23.5 (4.3)</td>
<td>22.1 (2.2)</td>
<td>0.226</td>
</tr>
<tr>
<td>Interval Between Scan and Follow-up (SD)</td>
<td>6.5 (2.3)</td>
<td>6.0 (1.9)</td>
<td>0.560</td>
</tr>
<tr>
<td>IQ (SD)</td>
<td>96.3 (22.3)</td>
<td>104.6 (11.9)</td>
<td>0.189</td>
</tr>
<tr>
<td>Years of Education (SD)</td>
<td>11.0 (2.5)</td>
<td>9.7 (1.2)</td>
<td>0.068</td>
</tr>
<tr>
<td>Young Mania Rating Scale (SD)</td>
<td>1.7 (2.6)</td>
<td>3.3 (3.8)</td>
<td>0.246</td>
</tr>
<tr>
<td>Mood State</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euthymic (%)</td>
<td>9 (82)</td>
<td>13 (68)</td>
<td>0.824</td>
</tr>
<tr>
<td>Depressed (%)</td>
<td>0 (0)</td>
<td>2 (11)</td>
<td>1.000†</td>
</tr>
<tr>
<td>Elevated f (%)</td>
<td>2 (18)</td>
<td>4 (21)</td>
<td>0.624</td>
</tr>
<tr>
<td>Prior Hospitalizations (%)</td>
<td>5 (45)</td>
<td>15 (79)</td>
<td>0.061</td>
</tr>
<tr>
<td>Rapid Cycling (%)</td>
<td>5 (45)</td>
<td>6 (32)</td>
<td>0.447</td>
</tr>
<tr>
<td>LifeTime Psychosis (%)</td>
<td>6 (55)</td>
<td>10 (53)</td>
<td>0.919</td>
</tr>
<tr>
<td>Suicide Attempt (%)</td>
<td>1 (9)</td>
<td>3 (16)</td>
<td>1.000†</td>
</tr>
<tr>
<td>Cigarette/Tobacco Use History at Baseline (%)</td>
<td>0 (0)</td>
<td>3 (16)</td>
<td>0.295</td>
</tr>
<tr>
<td>Simple/ Specific Phobia (%)</td>
<td>0 (0)</td>
<td>3 (16)</td>
<td>0.295</td>
</tr>
<tr>
<td>Attention Deficit Hyperactivity Disorder (%)</td>
<td>2 (18)</td>
<td>8 (42)</td>
<td>0.243</td>
</tr>
<tr>
<td>Oppositional Defiant Disorder (%)</td>
<td>1 (9)</td>
<td>2 (11)</td>
<td>1.000†</td>
</tr>
<tr>
<td>Conduct Disorder (%)</td>
<td>1 (9)</td>
<td>0 (0)</td>
<td>0.336</td>
</tr>
<tr>
<td>Separation Anxiety (%)</td>
<td>1 (9)</td>
<td>0 (0)</td>
<td>0.336</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicated at scan (%)</td>
<td>9 (82)</td>
<td>18 (95)</td>
<td>0.537</td>
</tr>
<tr>
<td>Antipsychotic (%)</td>
<td>6 (55)</td>
<td>12 (63)</td>
<td>0.645</td>
</tr>
<tr>
<td>Drug Type</td>
<td>Low (N=11)</td>
<td>High (N=19)</td>
<td>p value</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Anticonvulsant (%)</td>
<td>5 (45)</td>
<td>6 (32)</td>
<td>0.447</td>
</tr>
<tr>
<td>Stimulant (%)</td>
<td>2 (18)</td>
<td>8 (42)</td>
<td>0.24F</td>
</tr>
<tr>
<td>Lithium (%)</td>
<td>2 (18)</td>
<td>7 (37)</td>
<td>0.419F</td>
</tr>
<tr>
<td>Antidepressant (%)</td>
<td>2 (18)</td>
<td>3 (16)</td>
<td>1.000F</td>
</tr>
<tr>
<td>Benzodiazepine (%)</td>
<td>2 (18)</td>
<td>3 (16)</td>
<td>1.000F</td>
</tr>
<tr>
<td>Ketamine (%)</td>
<td>1 (9)</td>
<td>0 (0)</td>
<td>1.000F</td>
</tr>
<tr>
<td>Adrenergic Agonist (%)</td>
<td>0 (0)</td>
<td>1 (5)</td>
<td>1.000F</td>
</tr>
<tr>
<td>Amantadine (%)</td>
<td>0 (0)</td>
<td>1 (5)</td>
<td>1.000F</td>
</tr>
<tr>
<td>Levothyroxine (%)</td>
<td>1 (9)</td>
<td>3 (16)</td>
<td>1.000F</td>
</tr>
</tbody>
</table>

Age at baseline scan, age at follow-up, interval between scan and follow-up, IQ, years of education, and Young Mania Rating Scale scores were examined by a t-test to assess effect of CRAFFT group (CRAFFT<sup>HIGH</sup> versus CRAFFT<sup>LOW</sup>). All other factors were examined with Chi-square or Fisher’s exact tests.

F<sup>1</sup> represents p-value calculated with Fisher’s exact test.

Elevated mood includes subjects in hypomanic, manic, and mixed mood states.

Rapid-cycling reported is lifetime history of rapid cycling.

Presence of disorders of childhood were assessed by structured interview in subjects <18 years; percentage is based on the overall sample.

Individuals on levothyroxine had hypothyroidism. Results are shown across all subjects and when looking within males and within females separately.
Table 3  
Differences in Baseline CDRS and BIS Scores Between CRAFFT Follow-up Groups

<table>
<thead>
<tr>
<th></th>
<th>CRAFTT&lt;sub&gt;LOW&lt;/sub&gt;</th>
<th>CRAFTT&lt;sub&gt;HIGH&lt;/sub&gt;</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDRS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Subjects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20.7 (4.8)</td>
<td>28.1 (10.0)</td>
<td>0.045</td>
</tr>
<tr>
<td>Total BIS</td>
<td>62.2 (11.8)</td>
<td>67.7 (11.4)</td>
<td>0.278</td>
</tr>
<tr>
<td>Male Subjects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Nonplanning Impulsiveness</td>
<td>25.6 (4.6)</td>
<td>27.5 (5.8)</td>
<td>0.412</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Motor Impulsiveness</td>
<td>20.6 (6.2)</td>
<td>21.8 (5.4)</td>
<td>0.617</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Cognitive-Attentional Impulsiveness</td>
<td>16.1 (5.0)</td>
<td>18.4 (4.5)</td>
<td>0.265</td>
</tr>
<tr>
<td><strong>CDRS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Subjects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Nonplanning Impulsiveness</td>
<td>25.3 (3.8)</td>
<td>28.3 (4.7)</td>
<td>0.344</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Motor Impulsiveness</td>
<td>23.0 (5.3)</td>
<td>22.4 (3.4)</td>
<td>0.806</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIS Cognitive-Attentional Impulsiveness</td>
<td>18.7 (7.6)</td>
<td>20.4 (4.5)</td>
<td>0.633</td>
</tr>
</tbody>
</table>

CDRS and BIS (total and subscale) scores were examined by a t-test to assess effect of CRAFFT group (CRAFFT<sup>HIGH</sup> versus CRAFFT<sup>LOW</sup>). CDRS: N= 9 CRAFFT<sup>LOW</sup> (5 females), N= 18 CRAFFT<sup>HIGH</sup> (9 females); BIS: N= 8 CRAFFT<sup>LOW</sup> (3 females), N= 17 CRAFFT<sup>HIGH</sup> (9 females).